Just parking from the 10K.
(you wouldn't happen to know to whom they might owe milestones/royalties on the recombinant antibody licenses ...?)
Apologies for the formatting.
...As of July 31, 2003, 21 of our owned and licensed patents and patent applications relate to technologies or products in the C5 Inhibitor program, 10 relate to other technologies, 34 relate to the UniGraft program, 33 relate to the recombinant human antibody program and 1 relates to our high throughput compound screening program. We will owe royalties and other fees to the licensors of some of those patents and patent applications in connection with any future commercial manufacture and sale of our product candidates, including pexelizumab and eculizumab...
...In order to maintain its rights under these agreements, the Company may be required to provide a minimum level of funding or support. The Company may elect to terminate these arrangements. Accordingly, the Company recognizes the expense and related obligation related to these arrangements over the period of performance.
F-20
------------------------------------------------------------------------
Table of Contents
ALEXION PHARMACEUTICALS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
The minimum fixed payments (assuming non-termination of the above agreements) as of July 31, 2003, for each of the next five years are as follows (amounts in thousands):
Years
Ending
July 31,
------------------------------------------------------------------------
License
Agreements
------------------------------------------------------------------------
Research &
Development
Agreements
------------------------------------------------------------------------
Clinical &
Manufacturing
Development
Agreements
------------------------------------------------------------------------
2004 $ 367 $ 250 $ 15,720
2005 422 63 25,600
2006 447 — 23,400
2007 597 — 23,700
2008 842 — 24,100
Should the Company achieve certain milestones related to product development and product license applications and approvals, additional payments would be required. In addition to the payments above, as of July 31, 2003, these agreements contain milestone payment provisions aggregating approximately $49 million. The agreements also require the Company to fund certain future costs associated with the filing of patent applications... |
